Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in
Status
ACTIVE
Global HQ
San Francisco, USA
Countries of investment
  • Germany
  • France
  • Finland
  • Denmark
  • Sweden
  • Italy
Investment stages
  • Seed
  • Series A
  • Series B
Industries
  • Life Sciences
About
5AM Ventures is a leading venture capital firm focused on early-stage life sciences companies, primarily investing in seed and Series A rounds. Founded in 2002 and headquartered in San Francisco and Boston, 5AM supports companies developing groundbreaking biopharmaceuticals, drug delivery technologies, and life science instruments, partnering closely with entrepreneurs to translate scientific research into impactful healthcare innovations.
Min check size
$500K
Max check size
$10M
Fund size
NPS

Investment Thesis

5AM Ventures is a life science venture capital firm investing primarily in seed and early-stage biopharmaceutical and life science companies. The firm partners closely with academics and entrepreneurs to advance breakthrough science, focusing on drug delivery, medical devices, and related technologies.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

5AM Ventures focuses on early-stage life sciences companies, collaborating closely with academics and entrepreneurs to establish proof-of-concept and enable Series A financing.

5am Ventures Contacts Information

Primary contact

Secondary contact

Team

Kush M Parmar

MD

PhD – Managing Partner

Andy J. Schwab – Managing Partner

Michael Calore – Partner

Head of Investor Relations

John Kelly – Partner

Chief Financial Officer & Chief Operating Officer

Deborah Palestrant

PhD – Partner

Executive Chair

4:59 Initiative

Paul A. Stone

JD – Partner

Chief Legal Officer

Anna Yaeger – Partner

Head of Public Equities

Nicoletta Agostino – Senior Financial Analyst

Lindsay Ziegler Antonio – Compliance Manager

Kamila Bajerski – Assistant Controller

Andrew Booth – Venture Advisor

Rahul Bose – Senior Research Analyst

Jacquelyn Brough

CPA – Senior Vice President

Finance

Caroline Chamales – Senior Executive Assistant

Kevin Corsini Rosewood – Junior Executive Assistant

Office Manager

Lauren Daniel

JD – Chief Compliance Officer and Deputy General Counsel

Brian Daniels

MD – Venture Partner

Gisella de la Rocha

JD – Senior Corporate Counsel

4:59 Initiative

John D. Diekman

PhD – Founding Partner

Britt Inga Emerson – Investor Relations Manager

Max Farina

MD – Principal

Mason Freeman

MD – Venture Partner

Joshua Grass – Venture Partner

Steve Hitchcock

PhD – Venture Partner

Jane Johnstone – Associate Director

Legal

Peter S. Kim

PhD – Venture Advisor

Jennifer Kozub – Operations Manager and Executive Assistant

Elliott Levy

MD – Venture Partner

Jack Liu

PhD – Senior Research Analyst

Joe Loscalzo

MD

PhD – Venture Advisor

Vamsi Mootha

MD – Venture Advisor

Bella Nittolo – Administrative Assistant and Office Manager

Kori Rahaim – Senior Vice President

Head of People and 4:59 Initiative Business Operations

Scott M. Rocklage

PhD – Founding Partner

Paula Soteropoulos – Venture Partner

Katie Bodner Spielberg

PhD – Principal

Brian Stefanowicz

CPA – Controller

Aniqa Tasnim

PhD – Associate

Arthur Tzianabos

PhD – Venture Partner

Joseph J. Victor – Venture Advisor

Jonathan Weissman

PhD – Venture Advisor

Jennifer Zimmermann – Marketing Manager & Executive Assistant

Portfolio

Achaogen (AKAO)

Akouos (AKUS)

Alexza (ALXA)

Ambrx

Aprea (APRE)

Artiva Biotherapeutics (ARTV)

Arvinas (ARVN)

Audentes

Bellerophon (BLPH)

Bird Rock Bio

Cabaletta Bio (CABA)

Calibrium

Camp4 (CAMP)

Cellular Research

Ceterix

Chrono

Cidara (CDTX)

CinCor (CINC)

Crinetics (CRNX)

Dianthus Therapeutics (DNTH)

DVS

Enliven Therapeutics (ELVN)

Ensoma

Entrada (TRDA)

Envoy

Epirus (EPRS)

Escient Pharmaceuticals

Expansion Therapeutics

Flexion (FLXN)

GlycoEra

Halio

Inc.

Homology Medicines

Inc. (FIXX)

Ideaya Biosciences

Igenica

Ikaria

Ilypsa

Impel Neuropharma (IMPL)

Incline

Inipharm

KaloBios (KBIO)

Karius

Kinaset Therapeutics

Latigo

Lifordi

Magnetic Insight

Marcadia

Miikana

Millendo

nChroma Bio

Neurogastrx

Nido Bio

NodThera

Nouscom

Novira

Panomics

Pear (PEAR)

Pearl

PhaseRx (PZRX)

Portal

Precede Bio

PNI

Pulmatrix (PULM)

Purigen

Radionetics

Rallybio (RLYB)

RareCyte

Relypsa (RLYP)

Rennovia

Scientist.com

scPharmaceuticals (SCPH)

Semprus

Skye (SKYE)

Synosia

TMRW

VBI Vaccines

Viveve (VIVE)

Vor Biopharma (VOR)

Wildcat

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp